Hans Ehrencrona

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Johan Richter, Joëlle Guilhot, Franz Gruber et al. · The Lancet Oncology · 2018 · 611 citations · Full text

Medicine, Oncology, Pharmacology +11

Association of Type and Location of<i>BRCA1</i>and<i>BRCA2</i>Mutations With Risk of Breast and Ovarian Cancer

Timothy R. Rebbeck, Nandita Mitra, Fei Wan et al. · JAMA · 2015 · 509 citations · Full text

Medicine, Genetics, Oncology +17

Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer

Roger L. Milne, Karoline Kuchenbaecker, Kyriaki Michailidou et al. · Nature Genetics · 2017 · 471 citations · Full text

Medicine, Genetics, Oncology +12

Cancer Risks Associated With Germline<i>PALB2</i>Pathogenic Variants: An International Study of 524 Families

Xin Yang, Goska Leslie, Alicja Doroszuk et al. · Journal of Clinical Oncology · 2019 · 418 citations · Full text

Life Sciences, Genetics, Oncology +17

A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population

Antonis C. Antoniou, Xianshu Wang, Zachary S. Fredericksen et al. · Nature Genetics · 2010 · 342 citations · Full text

Medicine, Genetics, Oncology +17